RhoTM

lives impacted by Rho

Rho utilizes routinely captured x-rays to opportunistically identify patients at risk of osteoporosis.
‍

FAQ →

Request a Demo →

Get Started →

Licensed by Health Canada

FDA De Novo Marketing Authorization

80% of people aged 50+ undergo an x-ray.

RhoTM can analyze these x-rays for low bone mineral density.

Radiologist receives report for patients at risk.

Findings and recommendations are shared with the provider.

Provider develops personalized care plan with the patient.

Increased reimbursable services for at risk patients.

Clinical Risk Assessment

Fall Prevention

Lifestyle Modification

DXA Screening

Osteoporosis Care Reimagined.

Impacting care through AI-driven opportunistic screening.

Only

1 in 4

eligible women are currently screened for osteoporosis.

Up-to

50%

of men are never screened for osteoporosis.

RhoTM can utilize

80%

of imaging data captured during routine care.

Number of individuals with low BMD:

42 million

potential lives impacted.

Benefits to Our Customers

Finally, AI designed to improve outcomes for the patients you serve delivered through a value-based care model.

Leverage Existing Data

Increase Screening Rates

Increase Revenue

Maximize DXA Capacity

Cloud or On-Premise

PACS Integration